Skip to main content
. Author manuscript; available in PMC: 2018 Sep 8.
Published in final edited form as: Bioconjug Chem. 2018 Mar 1;29(4):914–927. doi: 10.1021/acs.bioconjchem.7b00816

Figure 4.

Figure 4.

(A) RA-TAX suppressed the growth of HepG2 subcutaneous tumors in vivo. Mice treated with RA-TAX filomicelles experienced 30% growth in tumors, while untreated tumors more than tripled in size during the same time frame. Free RA-TAX produced minimal retardation in tumor growth. (B) Orthotopic liver tumors established in vivo from HepG2 cells. RA-TAX treated tumors are 65% smaller than untreated tumors. (C) Quantification of liver tumor size from (B) and antihuman stain in adjacent liver lobe to identify number of HepG2 cells migrating. Quantification of cells staining positive is depicted in the bar graph. (D) Kaplan−Meier curve showing significant prolonged survival of RA-TAX treated mice with HepG2 liver tumors.